On February 28, 2014 MEI Pharma announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML) (Press release MEI Pharma, FEB 28, 2014, View Source [SID:1234500202]).
(Filing, 20-F, Theratechnologies, FEB 27, 2014, View Source [SID:1234504821])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Theratechnologies has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Press release Theratechnologies, FEB 27, 2014, View Source [SID1234500172]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program
Clovis Oncology aims for its first New Drug Application (NDA) submission by 2015. Lined up is a global Phase 3 registration study for rucaparib and plans to initiate registration studies for CO-1686 in the second quarter of 2014 (Press release Clovis Oncology, FEB 27, 2014, View Source [SID:1234500190]).
Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program
Clovis Oncology aims for its first New Drug Application (NDA) submission by 2015. Lined up is a global Phase 3 registration study for rucaparib and plans to initiate registration studies for CO-1686 in the second quarter of 2014 (Press release Clovis Oncology, FEB 27, 2014, View Source [SID:1234500190]).